Abstract
Background: Subsquamous intestinal metaplasia (SSIM) has been reported as an adverse outcome of endoscopic ablative therapy for dysplastic Barrett's esophagus (BE). However, the prevalence of SSIM in ablation-naïve patients with dysplastic BE is unknown, as is the response of SSIM to ablative therapy. Aim: To assess the prevalence of SSIM in ablation-naïve patients with BE containing HGD or LGD, and then to assess the prevalence of SSIM after ablative therapy. Methods: The AIM Dysplasia Trial is a U.S.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
